Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug - PubMed (original) (raw)
Review
doi: 10.1038/nrd839.
Affiliations
- PMID: 12120256
- DOI: 10.1038/nrd839
Review
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Renaud Capdeville et al. Nat Rev Drug Discov. 2002 Jul.
Abstract
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.
Similar articles
- Imatinib: a targeted clinical drug development.
Capdeville R, Silberman S. Capdeville R, et al. Semin Hematol. 2003 Apr;40(2 Suppl 2):15-20. doi: 10.1053/shem.2003.50037. Semin Hematol. 2003. PMID: 12783370 Review. - [Imatinib].
Urabe A. Urabe A. Gan To Kagaku Ryoho. 2003 Aug;30(8):1191-6. Gan To Kagaku Ryoho. 2003. PMID: 12938280 Review. Japanese. - Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Buchdunger E, et al. J Pharmacol Exp Ther. 2000 Oct;295(1):139-45. J Pharmacol Exp Ther. 2000. PMID: 10991971 - [Imatinib--a new perspective in the treatment of tumors].
Klener P, Klamová H. Klener P, et al. Cas Lek Cesk. 2004;143(9):579-80, 582-3. Cas Lek Cesk. 2004. PMID: 15532894 Review. Czech. - Imatinib as a paradigm of targeted therapies.
Druker BJ. Druker BJ. Adv Cancer Res. 2004;91:1-30. doi: 10.1016/S0065-230X(04)91001-9. Adv Cancer Res. 2004. PMID: 15327887 Review.
Cited by
- An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases.
J B, M BM, Chanda K. J B, et al. Front Chem. 2021 Mar 12;9:622286. doi: 10.3389/fchem.2021.622286. eCollection 2021. Front Chem. 2021. PMID: 33777895 Free PMC article. Review. - Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
Ventura F, Williams E, Ikeya M, Bullock AN, Ten Dijke P, Goumans MJ, Sanchez-Duffhues G. Ventura F, et al. Biomedicines. 2021 Feb 19;9(2):213. doi: 10.3390/biomedicines9020213. Biomedicines. 2021. PMID: 33669809 Free PMC article. Review. - Selective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) Complexes.
Sumaoka J, Akiba H, Komiyama M. Sumaoka J, et al. Int J Anal Chem. 2016;2016:3216523. doi: 10.1155/2016/3216523. Epub 2016 Jun 8. Int J Anal Chem. 2016. PMID: 27375742 Free PMC article. Review. - Prion degradation pathways: Potential for therapeutic intervention.
Goold R, McKinnon C, Tabrizi SJ. Goold R, et al. Mol Cell Neurosci. 2015 May;66(Pt A):12-20. doi: 10.1016/j.mcn.2014.12.009. Epub 2015 Jan 10. Mol Cell Neurosci. 2015. PMID: 25584786 Free PMC article. Review. - A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.
Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiok S, Colinge J, Superti-Furga G, Haura EB, Bennett KL. Chamrád I, et al. J Proteome Res. 2013 Sep 6;12(9):4005-17. doi: 10.1021/pr400309p. Epub 2013 Aug 20. J Proteome Res. 2013. PMID: 23901793 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical